XGX Pharma ApS: Financial statements 2023
CVR: 32289290
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
XGX Pharma ApS (CVR 32289290) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 8,100,823 and a net result of DKK 460,891 compared with DKK -1,842,554 the year before. That is an increase of 177.6% compared with the year before. Equity in the 2023 report amounted to DKK 14,259,628. The solvency ratio was 48.2%. The company had 5 employees in the financial year.
- Gross Profit
- DKK 8,100,823
- Profit/Loss
- DKK 460,891
- Equity
- DKK 14,259,628
- Total Assets
- DKK 29,601,202
- Employees
- 5
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 8.1 mio. | 461 t. | 14.3 mio. | 5 |
| 2022 | - | 2.9 mio. | -1.8 mio. | 13.8 mio. | 4 |
| 2021 | - | 14.5 mio. | 7.2 mio. | 13.2 mio. | 3 |
| 2020 | - | 15.2 mio. | 6 mio. | 12.9 mio. | 3 |
| 2019 | - | 11.7 mio. | 8.4 mio. | 11.4 mio. | 3 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
XGX Pharma ApS has published its annual report for 2022. Gross profit came to DKK 2,917,678, and the net result was DKK -1,842,554.
About XGX Pharma ApS
XGX Pharma ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2009. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named VITAL PHARMA NORDIC ApS and VITAL PHARMA NORDIC HOLDING ApS. The management consists of Jens-Nikolaj Schøier. The board consists of Per Anders Larnholt (chair) and Johan Frödin. The company is owned by Unimedic Pharma AB. The company has 6 employees (2026). In 2025, the company reported a gross profit of DKK 32,338,381 and a net result of DKK 16,074,119 compared with DKK 4,453,433 the year before. Equity in the 2025 report amounted to DKK 30,787,180.